Results 241 to 250 of about 273,293 (311)

The multiple hit model of infantile and epileptic spasms: The 2025 update

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou   +6 more
wiley   +1 more source

Author response: Sphingosine 1-phosphate-regulated transcriptomes in heterogenous arterial and lymphatic endothelium of the aorta

open access: gold, 2019
Eric Engelbrecht   +15 more
openalex   +1 more source

Extracellular Vesicle‐Based mRNA Therapeutics and Vaccines

open access: yesExploration, EarlyView.
This review provides a comprehensive analysis of recent advancements in extracellular vesicle (EV)‐based messenger RNA (mRNA) applications for therapeutics and vaccines. It systematically outlines strategies for mRNA encapsulation within EVs and elucidates the challenges associated with this technology, offering insights into future research directions
Qi Li   +6 more
wiley   +1 more source

Chloride Intracellular Channel 2 Can Function as a Malignant Factor in Head and Neck Squamous Cell Carcinoma

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The association of chloride intracellular channel 2 (CLIC2) with tumors has remained unclear. However, recently, CLIC2 was found to exhibit antitumor properties in some tumors. In this study, we aimed to evaluate the clinical relevance of CLIC2 expression in head and neck squamous cell carcinoma (HNSCC) to determine whether it ...
Yuki Hosokawa   +9 more
wiley   +1 more source

Targeted volume imaging reveals early vascular interactions of Lyme disease pathogen in skin. [PDF]

open access: yesNat Commun
Strnad M   +5 more
europepmc   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy